Celldex Therapeutics (CLDX) Target Raised to $39 at Cantor
Tweet Send to a Friend
Cantor Fitzgerald maintained a Buy rating on Celldex Therapeutics (NASDAQ: CLDX) and raised its price target to $39.00 (from $24.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE